Vol. 4 No. 11 (2024)
Reimbursement Reviews

Remdesivir (Veklury)

Published November 25, 2024

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses remdesivir (Veklury), 100 mg/vial, IV infusion.
  • Indication: For the treatment of COVID-19 in nonhospitalized adults and pediatric patients (weighing ≥ 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization and death.